CME Group (CME) director receives 645-share fully vested equity grant

Rhea-AI Filing Summary

Lockett Phyllis M reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Phyllis M. Lockett received an equity award of 645 shares of Class A common stock on June 25, 2026. The award was granted at $225.00 per share as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.

These shares are fully vested and not subject to any vesting conditions, meaning Lockett has immediate ownership rights. Following this grant, she directly holds 4,285 shares of CME Group Class A common stock, reflecting routine, compensation-related share ownership rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lockett Phyllis M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K

Holdings After Transaction: Common Stock Class A — 4,285 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant size: 645 shares Grant reference price: $225.00 per share Post-transaction holdings: 4,285 shares

3 metrics

Equity grant size 645 shares Class A common stock grant on June 25, 2026

Grant reference price $225.00 per share Price per share reported for the 645-share award

Post-transaction holdings 4,285 shares Total Class A common shares directly owned after grant

Key Terms

annual equity compensation program, CME Group Director Stock Plan, fully vested shares

3 terms

annual equity compensation program financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors"

CME Group Director Stock Plan financial

"for non-employee directors under the CME Group Director Stock Plan"

fully vested shares financial

"Represents a grant of fully vested shares of Class A Common Stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:19 PM Accepted by SEC EDGAR 06/29/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lockett Phyllis M

(Last) (First) (Middle)

20 S. WACKER DR.

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2026		A(1)		645	A	$225	4,285	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Phyllis M. Lockett	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CME (CME) director Phyllis M. Lockett report in this Form 4?

Director Phyllis M. Lockett reported receiving an award of 645 shares of CME Group Class A common stock. The grant is part of the company’s equity compensation for non-employee directors and increases her direct holdings to 4,285 shares after the transaction.

Was the CME (CME) insider transaction a market buy or sell?

The transaction was not a market buy or sell. Lockett received 645 fully vested shares as a grant under CME Group’s director equity compensation program, classified as a grant, award, or other acquisition rather than an open-market transaction.

How many CME Group (CME) shares does Phyllis M. Lockett hold after the grant?

After the grant, Phyllis M. Lockett directly owns 4,285 shares of CME Group Class A common stock. This total includes the newly awarded 645 fully vested shares from the company’s annual equity compensation program for non-employee directors.

Are the granted CME (CME) shares to Phyllis M. Lockett subject to vesting conditions?

The 645 granted shares are not subject to vesting conditions. The filing states they are fully vested Class A common shares issued under the CME Group Director Stock Plan, giving Lockett immediate ownership and rights without a future vesting schedule.

What program governed the 645-share grant reported for CME (CME)?

The 645-share grant was issued under the CME Group Director Stock Plan. It represents annual equity compensation for non-employee directors, providing fully vested Class A common stock as part of the company’s standard board compensation structure.